Ultragenyx Pharmaceutical Inc.
As of Oct 22, 2026, Ultragenyx Pharmaceutical is in Stage 4, the downtrend phase, now in week 6 (since Sep 16, 2026). It closed at $15.95, 56.3% below its 52-week high and below its 200-day average, which is falling.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare g… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RARE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RARE among Biotechnology361st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …361 | RARE | Stage 4 · wk 6 | 22 | +7.2% |
Ultragenyx Pharmaceutical: quick answers
What stage is Ultragenyx Pharmaceutical in?
As of Oct 22, 2026, Ultragenyx Pharmaceutical (RARE) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Ultragenyx Pharmaceutical in an uptrend?
No. Ultragenyx Pharmaceutical is in a Stage 4 downtrend. It trades 31.0% below its 200-day average, which is falling.
How far is Ultragenyx Pharmaceutical from its 52-week high?
Ultragenyx Pharmaceutical closed at $15.95 on Oct 22, 2026, 56.3% below its 52-week high of $36.54. Its 52-week low is $12.88.
How has Ultragenyx Pharmaceutical performed over the past year?
As of Oct 22, 2026, Ultragenyx Pharmaceutical is down 53.3% over the past year and down 32.4% so far in 2026.
Which sector and industry is Ultragenyx Pharmaceutical in?
Ultragenyx Pharmaceutical is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.